Short Bowel Syndrome Clinical Trials

NCT ID: NCT05441345 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Sarcopenia and Short Bowel Syndrome

SARCO-SGC

Start date: August 18, 2022
Phase:
Study type: Observational

Sarcopenia or the loss of skeletal muscle is highly prevalent in many diseases, including short bowel syndrome (SBS). While adaptation is more likely in SBS patients with a colon-in-continuity, the consequences and underlying mechanisms are unclear. An overabundance of fecal Lactobacillus was found but not yet linked to adaptation or sarcopenia. The objectives are to study the evolution of sarcopenia and the link with intestinal adaptation in SBS.

NCT ID: NCT05018286 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

STARS extend

Start date: July 13, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.

NCT ID: NCT04522778 Active, not recruiting - Quality of Life Clinical Trials

Innovative Central Line Securement Device in the Pediatric Population

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

This study involves evaluating pediatric patients with central lines to determine differences in line complications and quality of life in those with a novel central line securement device (wrap) as compared to those who use a traditional securement device (dressing).

NCT ID: NCT04379856 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Proof of Concept Study in Patients With Short Bowel Syndrome

Start date: June 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide. NM-002 is planned to be administered twice, at up to 3 different dose levels, in up to 3 cohorts, each consisting of 3-4 patients. Doses will be administered on Days 1 and 15 by subcutaneous injection. Patients will be monitored for their usage of parenteral supplementation, and will fill out a daily diary for their symptoms of SBS. Urine output will be measured on a daily basis. Patients will be followed for 6 weeks after the second dose.

NCT ID: NCT03773237 Active, not recruiting - Crohn Disease Clinical Trials

Intralipid Versus SMOFlipid in HPN Patients

Start date: December 31, 2018
Phase: N/A
Study type: Interventional

This study will randomize all patients who are new to the Mayo Clinic HPN team to either standard lipid emulsion (Intralipid) or SMOFLipid.

NCT ID: NCT01990040 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Registry for Participants With Short Bowel Syndrome

Start date: June 23, 2014
Phase:
Study type: Observational [Patient Registry]

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

NCT ID: NCT00793195 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine the feasibility of conducting a trial to examine the efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and early liver dysfunction.

Short Bowel Syndrome clinical trials